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Objective: Saphenous vein grafting is associated with extensive medial
remodeling, characterized by cellular proliferation, loss of smooth muscle
cells, and an inflammatory response. In this study, we examined whether
unfavorable responses to vein grafting could be modified by the intraoper-
ative application of c-myc antisense oligomers. Methods: The intragraft cell
proliferation, macrophage infiltration, and medial preservation were exam-
ined in a porcine model in the control and antisense-treated groups (n 5
36). Results: Saphenous veins showed transmural distribution of oligomers
within 30 minutes of the ex vivo incubation. A concentration-dependent
inhibition of cell proliferation in the media of saphenous grafts was noted
3 days later (0 to 200 mmol/L, p 5 0.005). The growth inhibition was
sequence-specific, because control oligomers produced only insignificant
effects (20 mmol/L). Vascular effects of c-myc antisense were associated with
a significant attenuation of macrophage infiltration in saphenous grafts. A
concentration-dependent decrease in tissue edema (p 5 0.0005) and the
attenuated loss of smooth muscle cells (p 5 0.002) were noted in the media
of the arterialized venous conduits after c-myc antisense. Conclusions:
Direct application of synthetic DNA to harvested saphenous veins resulted
in a rapid transmural distribution. The inhibition of the intragraft cell
proliferation in vivo after c-myc antisense was sequence dependent. De-
crease in vein graft injury resulted in an attenuated inflammatory response
and better medial preservation. These findings provide a rationale for
assessment of the long-term effects of vein graft protection with c-myc
antisense. (J Thorac Cardiovasc Surg 1998;115:152-61)
Bypass grafting with autologous saphenous veinhas become the cornerstone of therapy for ob-
structive coronary artery disease since its introduc-
tion by Favaloro in 1969.1 Clinical outcomes of this
procedure, however, are marred by a progressive
loss of saphenous vein graft (SVG) patency, which is
particularly accelerated at later years.2, 3 The preex-
isting changes in saphenous vein may have an im-
pact on the fate of SVGs.4 More important, how-
ever, vascular injury is commonly induced by
grafting.5-7 These changes are accompanied by the
rapid activation of immediate-early gene expression,
including c-fos and c-myc protooncogenes, and con-
tribute to cell proliferation.8 Subsequent events,
including thrombosis, intimal formation, and even
late graft atherosclerosis, can be viewed as the
response to ubiquitous vascular injury that develops
after vein arterialization.
Our previous observations indicated the presence
of intragraft cell proliferation and suggested migra-
tion of myofibroblasts through the injured media to
neointima.9 The accompanying changes resemble
the process of wound healing and may result in
unfavorable remodeling of the conduit.10, 11 The
intima, which often replaces damaged media, be-
comes the nidus for future atherosclerotic plaque.12
On the basis of these observations, we examined the
hypothesis that early changes in SVGs can be atten-
uated by the intraoperative application of an inter-
vention aimed at controlling cell proliferation. In
this study, we report concentration-dependent ef-
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fects of synthetic antisense DNA directed against
the c-myc protooncogene in porcine SVGs. The
results demonstrate reduction in cell proliferation
and improved preservation of the media in SVGs.
These data provide a rationale for the future exam-
ination of this strategy to improve the long-term
patency of SVGs.
Methods
Animal preparation. A porcine model of SVG interpo-
sition in the common carotid artery was used.7, 9, 10 After
medication with aspirin (650 mg orally) and cefazolin (1
gm intravenously), crossbred pigs (n 5 36, 22 to 55 kg)
were sedated with ketamine (20 mg/kg intramuscularly)
and xylazine (4 mg/kg intramuscularly). The anesthesia
was maintained with endotracheal halothane (0.75%) and
oxygen. Lateral saphenous veins (6 to 10 cm) were iso-
lated and then incubated in a saline solution bath (total
volume 10 ml) with either no oligomers or various se-
quences, as described later. The carotid arteries were
dissected free and heparin sodium (150 units/kg intrave-
nously) was administered. After a 2 cm portion of the
carotid artery was excised, the proximal end was anasto-
mosed with a continuous suture, and a similar procedure
was performed on the distal anastomosis. The incision was
closed, and the animals were allowed to recover. Repli-
cating cells in SVGs were labeled in vivo with an intrave-
nous injection of 5-bromo-29-deoxyuridine (30 mg/kg
BrdU; Boehringer Mannheim Corp., Indianapolis, IN) 2
hours before the animals were euthanized.
The animals were euthanized with an intravenous over-
dose of Euthasol (Delmarva Laboratory, Midlothian, VA)
containing pentobarbital sodium (1950 mg) and phenytoin
sodium (250 mg) 3 days after the operation. All proce-
dures were in accordance with institutional guidelines and
in compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Labo-
ratory Animal Resources and published by the National
Institutes of Health (NIH Publication No. 86-23, revised
1985).
Oligomer preparation and application. Phosphoro-
thioate oligomers were synthesized by an automated
deoxyribonucleic acid (DNA) synthesizer and purified by
high-pressure liquid chromatography (Lynx Therapeutics,
Hayward, CA). Table I depicts oligomer sequences that
were used in this study. For vascular distribution studies,
antisense oligomers were labeled with carboxyfluoresceins
as described by the manufacturer (Applied Biosystems,
Foster City, CA). Freshly excised saphenous veins were
then incubated with oligomers for 2 seconds, 30 minutes,
and 1 hour. For in vivo studies, individual saphenous veins
were randomly assigned to different concentrations of
antisense DNA (0, 2, 20, and 200 mmol/L) or different
oligomer sequence (no oligomer, antisense, scrambled, or
mismatched) as indicated in the text. After the 30-minute
incubation period in the respective solution, saphenous
veins were interposed in the carotid artery and the
remaining bath solution was topically applied to the
perigraft region.
Tissue sampling, preservation, and processing. The
distribution of fluorescent-labeled oligomers was examined
in formalin-fixed (6 hours) and paraffin-embedded saphe-
nous veins. Serial sections (4 mm thick) were removed from
paraffin and covered with SlowFadeLight antifading reagent
(Molecular Probes, Inc., Eugene, OR), and fluorescent-
labeled oligomers were visualized under a Nikon Optiphot
microscope (Nikon Inc., Instrument Group, Melville, NY).
The conditions were optimized with a narrow-band filter
(excitation 485 6 10 nm) that eliminated the autofluores-
cence in the control saphenous veins.
In the remaining experiments, carotid arteries were ex-
posed at the time of SVG harvesting. Distal ends were
opened to demonstrate pulsatile blood flow and ensure graft
patency in situ. Occluded vessels were excluded from further
analysis (0, 3, 2, and 4 in 0, 2, 20, and 200 mmol groups,
respectively, not significant), whereas patent vessels were
excised with surrounding tissues and immersed in Histo-
Choice fixative (Amresco, Solon, OH) for at least 5 hours.
They were sectioned (5 mm blocks), processed in a Tis-
sueTek vacuum infiltration processor (Miles Scientific, Na-
perville, IL), and embedded in paraffin. The sections (5 mm
thick) from each block were stained with Verhoeff’s stain to
determine the overall vessel structure. Multiple sections
from at least three blocks representing the body of the graft
were selected for this study. The n values reported in the
Results section represent the number of vessels.
Immunohistochemistry. The Vectastain Elite ABC sys-
tem (Vector Laboratories, Inc., Burlingame, CA) was
used as previously described.9 The following primary
antibodies were used: a monoclonal mouse antibody
recognizing BrdU (1:200, Novocastra Laboratory, Ltd.,
Newcastle Upon Tyne, UK), a monoclonal mouse DE-
R-11 antibody recognizing intermediate filament desmin
(1:50; Novocastra); a monoclonal mouse antiporcine mac-
rophage immunoglobulin G2b antibody (1:10, ATCC HB
142.1; American Type Culture Collection, Rockville,
MD). Afterward, slides were incubated with biotinylated
secondary horse antimouse immunoglobulin G (1:2000;
Vector Laboratories) for 1 hour. They were then stained
with diaminobenzidine tetrahydrochloride substrate kit
(Vector Laboratories) followed by counterstain with Gill’s
hematoxylin (Sigma Diagnostics, St. Louis, MO). Positive
control preparations for desmin included sections of
Table I. C-myc mRNA and oligomer design used in
the study
Name Sequences (593 39)
Human c-myc
mRNA
...CG AUG CCC CUC AAC GUU AG...
Porcine c-myc
mRNA
...CG AUG CCC CUC AAC GUC AG...
Antisense AAC GTT GAG GGG CAT
Scrambled GAA CGG AGA CGG TTT
Mismatched AAG CAT ACG GGG TGT
Human and porcine c-myc mRNA sequences are shown for comparison.
The AUG region represents the first codon of the second exon of c-myc
mRNA. The antisense sequence contains 15 nucleotides complementary to
human c-myc mRNA and one nucleotide mismatch compared with porcine
mRNA. Nucleotides shown in italics represent mismatches with porcine
mRNA, whereas contiguous guanosines (4G motif) are underlined.
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porcine coronary arteries and normal human saphenous
veins. For the antimacrophage antibody, positive control
preparations consisted of lung alveolar macrophages.
Negative control procedures were carried out with non-
immune serum instead of primary antibody.
Data analysis. To examine concentration- or sequence-
dependent effects of oligomers on cell proliferation, cells
showing BrdU in at least three different sections from
each graft were counted without the knowledge of random
assignment. To avoid selection bias, quantitative measure-
ments were carried out in the entire media under the same
magnification; mean values were then calculated. Histo-
logic markers of vein graft injury (vessel morphometry,
desmin immunostaining, macrophage count) were ana-
lyzed in serial sections adjacent to those with the highest
number of BrdU-labeled cells in each vessel to account for
the focal changes after vein grafting. To quantify medial
changes (vessel morphometry, desmin immunostaining),
the sections were digitized with a Sony DXC-750MD
video camera (Sony Corporation, Tokyo, Japan) attached
to a Nikon Optiphot-2 microscope. To obtain medial
areas, sections stained with Verhoeff’s stain were then
processed with a video analysis software package (Media
Cybernetics, Silver Spring, MD). To quantify the loss of
medial smooth muscle (SM) cells after grafting, digitized
images of desmin immunostaining were analyzed with the
Image-Pro software (Media Cybernetics). From each ves-
sel, a microscopic field exhibiting the worst medial dam-
age was selected. The area occupied by desmin was then
automatically quantified and expressed as the percentage
of media.
Numeric data are presented as mean 6 standard error.
To determine whether the effects of c-myc antisense DNA
were concentration dependent, statistical significance was
calculated with linear regression analysis. Furthermore,
analysis of variance was carried out to examine the overall
differences in multigroup comparisons. If a significant p
value was present, Bonferroni correction was used to
identify specific intergroup differences. A p value of less
than 0.05 was considered statistically significant.
Results
Distribution of antisense DNA in saphenous vein
conduits. To examine the distribution and time
course of oligomer uptake in saphenous veins,
freshly harvested segments were incubated ex vivo
with fluorescent-labeled antisense DNA (200
mmol/L) for 2 seconds, 30 minutes, and 1 hour. As
shown in Fig. 1, transmural distribution of oligomers
was apparent after 30 minutes. Nuclear localization
of the label pointed to the intracellular uptake of
antisense DNA. A similar transmural distribution of
Fig. 1. Time-dependent vascular distribution of fluorescent oligomers. Human saphenous vein segments
were incubated ex vivo with c-myc antisense DNA (200 mmol/L) and examined by fluorescent microscopy.
A, At 2 seconds, fluorescence is visible only along luminal and adventitial surfaces, whereas the media (m)
is devoid of oligomers. Note the absence of autofluorescence in the media. B, At 30 minutes, transmural
distribution of oligomers is associated with nuclear localization of fluorescence. C, At 1 hour, the media
(m) is further saturated with labeled oligomers. Experiments were repeated three times, yielding similar
results. (Magnification 325.)
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oligomers was also evident by direct perivascular
application of oligomers to the vessels in situ (not
shown), which suggested that the pattern of oli-
gomer uptake was not related to tissue damage
associated with vein isolation. On the basis of these
results, the 30-minute incubation period was se-
lected for the remaining in vivo experiments.
Antiproliferative effect of antisense DNA in SVGs.
A dose response regarding the inhibition of cell
proliferation was established in SVGs in vivo. Me-
dial cell proliferation was compared after the appli-
cation of no oligomers (n 5 6) or c-myc antisense
DNA at concentrations of 2 mmol/L (n 5 5), 20
mmol/L (n 5 6), and 200 mmol/L (n 5 6). Fig. 2
illustrates the intragraft cell proliferation (BrdU
labeling), which was decreased in a dose-dependent
manner by antisense DNA (p 5 0.005). As summa-
rized in Fig. 3, proliferative responses were signifi-
cantly reduced at 20 mmol/L (decreased by 60%)
and 200 mmol/L concentrations (decreased by 82%)
at 3 days after the treatment.
To examine whether the antiproliferative actions
of antisense DNA are sequence dependent, as op-
posed to the effects related to phosphorothioate
backbone (sequence independent) or the presence
of four contiguous guanosine residues (4G motif),
we also compared the inhibition of cell proliferation
in vivo with two different control sequences. As
shown in Table II, antisense produced the most
pronounced inhibition of the intragraft cell prolifer-
Fig. 2. Cell proliferation in porcine SVGs. Harvested saphenous veins were treated with no oligomers (A)
or with c-myc antisense DNA at concentrations of 2 mmol/L (B), 20 mmol/L (C), or 200 mmol/L (D).
Proliferating cells were labeled in vivo with BrdU at 3 days after vein interposition into the carotid arteries.
BrdU-labeled cells (brown nuclei) are decreased in the media (m) of SVGs treated with 20 mmol/L and 200
mmol/L of c-myc antisense DNA. Arrows point to the border between the media (m) and adventitia.
Labeled cells outside the media represent proliferating cells in the adventitia and perivascular wound.
(Magnification 3150.)
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ation (p 5 0.02), whereas scrambled oligomers or
mismatched sequences (4G motif) were devoid of
significant effects. It is noteworthy, however, that
control oligomers with 4G motif produced some
decrease in cell proliferation in vivo at equimolar
concentrations.
Reduction of inflammatory response after anti-
sense DNA treatment. The changes associated with
saphenous vein grafting include an inflammatory
response, which may increase graft injury. Accord-
ingly, we compared macrophage content in the
untreated and the antisense-treated SVGs 3 days
after the operation (Fig. 4). Total macrophage con-
tent was significantly reduced from 587 6 153
cells/graft in saphenous veins incubated without
oligomers (n 5 6) to 159 6 52 (20 mmol/L, n 5 6,
p 5 0.03) and 104 6 26 cells/graft (200 mmol/L, n 5
6, p 5 0.02) after c-myc antisense DNA treatment.
As shown in Fig. 5, these differences were due
mainly to the decrease in infiltrating macrophages,
whereas the reduction in adhering macrophages did
not reach statistical significance.
Medial preservation after antisense DNA. As
shown in Fig. 6, the untreated SVGs typically dem-
onstrated several microscopic characteristics consis-
tent with medial injury (focal cell infiltrates, cellular
debris, and intramural hematoma or edema). This
contrasted with the antisense-treated grafts, which
exhibited better-preserved media (Fig. 6). To fur-
ther examine the vasculoprotective effects of anti-
sense DNA, we quantified the markers of medial
preservation. A concentration-dependent (0, 20
mmol/L, 200 mmol/L; p 5 0.0005) reduction in
medial edema was indicated by the decrease in
medial areas after the treatment (Fig. 7). To confirm
that these effects were associated with the improved
SM cell retention, the distribution of desmin (a
marker of SM cells) was also analyzed. As illustrated
in Fig. 8, the untreated vein grafts typically showed
focal loss of SM cells, whereas the antisense-treated
veins showed better preservation of desmin. These
effects were concentration dependent (0, 20 mmol/L,
200 mmol/L; p 5 0.002). The retention of desmin in
the media is summarized in Fig. 9.
Discussion
Cell proliferation is recognized as a typical re-
sponse of vascular tissues to injury. This phenome-
non may contribute to undesirable sequelae, such as
SVG degeneration after revascularization proce-
dures.9, 10 This study demonstrated rapid develop-
ment of cell proliferation and medial injury in the
arterialized SVGs. The intraoperative incubation of
saphenous veins with antisense DNA against c-myc
conferred significant vasculoprotective effects, re-
flected by the reduction in cell proliferation and the
decrease in several markers of medial injury.
Sequence-dependent effects of “antisense” DNA.
Vascular applications of antisense have been based
on a premise that synthetic DNA complementary to
messenger ribonucleic acid (mRNA) of a cell-cycle–
regulating gene can block the proliferative reaction
by means of DNA-mRNA hybridization.13, 14 It
should be emphasized, however, that antisense
DNA oligomers are pleiotropic compounds that
may exert their biologic effects through several
mechanisms. Phosphorothioate backbone prolongs
oligomer bioavailability, but it may also contribute
to effects unrelated to oligomer-mRNA hybridiza-
Fig. 3. Bar graph illustrating reduction in medial cell
proliferation after c-myc antisense DNA in SVGs. Results
are presented as mean 6 standard error, with p values
referring to comparisons between treatment and control
(no oligomers) groups.
Table II. Sequence-dependent effects of c-myc
antisense oligomers on cell proliferation in vivo
Sequence n Proliferation D (%) p
Antisense 8 2 65 6 6 0.02
Scrambled 8 1 6 6 23 NS
Mismatched 8 2 29 6 11 NS
Oligomers were applied in equimolar concentrations (20 mmol/L). Cell
proliferation was assessed by the number of BrdU-labeled cells in the
media of the graft at 3 days after the treatment (random allocation).
Changes (D) were calculated as a percentage in comparison with the
control group (n 5 8, no oligomers). Negative values represent a reduction
in cell proliferation; positive value refers to an increase. Results are
presented as mean 6 standard error, p value refers to intergroup compar-
isons with control group (analysis of variance followed by Bonferroni’s
correction).
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tion.15 It is important to recognize that even some
sequence-dependent phenomena are related to in-
teractions with growth factors (e.g., basic fibroblast
growth factor), thereby augmenting antiproliferative
effects.16 This study demonstrated sequence-depen-
dent reduction in medial cell proliferation in SVGs,
whereas scrambled phosphorothioate sequence ex-
hibited no effects in vivo (Table II). These findings
underscore the dichotomy between in vitro and in
vivo systems, with the former more likely to elicit
sequence independent effects.15-17 We also tested a
mismatched sequence containing 4G motif, notori-
ous for several nonantisense effects in cell cul-
ture.17, 18 When different oligomers were compared
in vivo with approximately the median effective
concentration, control sequence with 4G motif did
not demonstrate a significant decrease in cell prolif-
eration. Accordingly, the antiproliferative effects of
antisense DNA in vivo cannot be attributed solely to
the presence of contiguous guanosine residues.
However, the present findings do not exclude the
possibility that 4G motif confers additive antiprolif-
erative effects at higher concentrations.
The intracellular accumulation of intact anti-
sense oligomers is associated with downregulation
of c-myc expression in cells derived from saphenous
veins.14 Nonetheless, because the c-myc gene repre-
sents a common final pathway in the growth regu-
lation of vascular cells, a wide range of other growth
inhibitors may reduce its expression without direct
interactions with target mRNA.19 Accordingly,
downregulation of the target mRNA or protein is
not sufficient to discern between overlapping anti-
sense (oligomer-mRNA hybridization) and nonan-
tisense (e.g., growth-factor inhibition) mechanisms.
Fig. 4. Inflammatory response in SVGs. A, Untreated saphenous veins exhibited focal accumulation of
macrophages in the media (dark brown staining). B, Treatment with c-myc antisense oligomers (200
mmol/L) was associated with attenuated inflammatory response 3 days after the operation. Note the
decrease in infiltrating macrophages in the media of the graft, whereas adhering macrophages at the
luminal side were less affected. Arrows point to the border between the media and adventitia. Labeled cells
outside the media represent macrophages in the adventitia and perivascular wound. (Magnification 3150.)
Fig. 5. Bar graph illustrating changes in inflammatory
response in SVGs after treatment with c-myc antisense
oligomers. Total macrophage content and infiltrating
macrophages in the media were significantly reduced in
treated groups. The number of adhering macrophages,
although reduced, did not reach statistical significance.
Results are presented as mean 6 standard error, with p
values referring to comparisons between control (oli-
gomers) and individual treatment groups (20 mmol/L and
200 mmol/L).
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Taking into consideration these observations, we
prefer to describe the effects of c-myc antisense
oligomers as sequence dependent, rather than cate-
gorically describe them as purely antisense.
The role of media in vascular response to injury.
The observed changes in the SVGs have under-
scored a rapid development of medial injury, con-
sistent with previous experimental and clinical find-
ings.6, 20 The activation of vascular fibroblasts with
their differentiation to myofibroblasts develops after
severe medial injury in coronary arteries.21, 22 Al-
though the changes in SVGs differ from the arterial
response to injury, some aspects of vascular repair
are common.23 Both perivascular and medial fibro-
blasts contribute to the repair of porcine arterialized
saphenous veins translocating to the neointima.9
Likewise, human saphenous veins in organ culture
preferentially acquire neointima from the adventitia
or the edges of broken media (repositories of vas-
cular fibroblasts), but not from the intact media,
despite stimulation with growth factors.24 These
observations underscore the notion that the preser-
vation of the media in SVGs may have an impact on
long-term patency.
The origin of medial damage after saphenous vein
grafting is multifactorial. In addition to tissue injury
during surgical harvesting, the activation of cells in situ
and medial infiltration with blood-borne inflammatory
cells may induce local cytotoxic effects. The latter is
particularly important because invading macrophages
often perpetuate tissue damage.25 A highly distinct
mechanism leading to medial loss may be represented
by apoptosis, which colocalizes in the regions of high
proliferation and c-myc expression.26 The results of
this study demonstrate that c-myc antisense DNA
attenuates several markers of tissue damage after SVG
arterialization. The improvement in histologic preser-
vation of medial SM cells, paralleled as it is by the
Fig. 6. Photomicrographs showing the media of SVGs (Verhoeff’s stain). A, Untreated grafts demonstrated
medial edema, focal necrosis, and, frequently, adhering layer of thrombus. Note disorganized cells in the media.
B, Treatment with c-myc antisense oligomers (200 mmol/L) was associated with reduction of medial edema and
overall better preservation of SM cells in the graft. Note circumferential alignment of SM cells in the media.
Arrows point to the border between the media (m) and adventitia. (Magnification 3150.)
Fig. 7. Bar graph depicting changes in medial areas of
SVGs after c-myc antisense oligomers. Medial areas are
significantly smaller in the treated group (200 mmol/L) as
a result of marked reduction in tissue edema and inhibi-
tion of inflammatory response. Results are presented as
mean 6 standard error, with p values referring to com-
parisons between treatment and control (no oligomers)
groups.
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decrease in macrophage infiltration, points to the
possibility of vascular protection after arterialization.
Antisense DNA as a therapeutic agent. Antisense
DNA sequences against several growth-regulatory
genes have been envisioned for the prevention of
coronary restenosis.27, 28 We previously showed the
reduction in neointimal formation after antisense
oligomers against the c-myc in a porcine model of
coronary injury.28 This approach, however, is hin-
dered by a low efficiency of transcatheter delivery
(,1%). In contrast, direct ex vivo application of
antisense DNA to the SVG results in the uniform
distribution of oligomers after 30 minutes of incu-
bation, involving not only the adventitia but also the
entire media. This is particularly important for
SVG, because the events in the media may contrib-
ute to late graft failure. Because the treatment of
saphenous veins occurs ex vivo, the risk of potential
side-effects in regions remote from the site of appli-
cation of antisense DNA is probably minimized.
Furthermore, it is noteworthy that identical anti-
sense DNA has demonstrated no significant adverse
effects even after the intracoronary administration
in patients after coronary angioplasty.29 The ques-
tion of whether the short-term effects of c-myc
antisense, as demonstrated in the current study, will
translate to a long-term benefit regarding remodel-
ing of the arterialized grafts requires separate stud-
ies. It should be underscored, however, that medial
injury appears to occur early, so SVG protection
may not necessarily require prolonged or repeated
drug administration. Alternative approaches may
include attempts to prolong the bioavailability and
cellular uptake of oligomers by complexing them
with liposomes.30
In conclusion, antisense DNA against the c-myc
protooncogene can easily be delivered to harvested
saphenous veins used for arterial revascularization,
thus achieving the uniform distribution of oligomers
Fig. 8. SM cell preservation in SVG. A, Untreated grafts demonstrated focal loss of SM cell marker,
desmin. Remaining medial SM cells (brown cytoplasmic stain) are interspersed with cell debris and
nonmuscle cells. B, Marked retention of SM cells in the media was present in SVGs treated with c-myc
antisense oligomers (200 mmol/L). Note the paucity of tissue edema and restored microarchitecture of the
vein. Arrows point to the border between the media (m) and adventitia. (Magnification 3150.)
Fig. 9. Bar graph showing retention of SM cells in SVGs
after treatment with c-myc antisense oligomers. In areas
with maximal histologic medial injury, desmin distribution
was quantified. In the antisense-treated group (200 mmol/
L), SM retention was significantly improved compared
with untreated grafts. Results are presented as mean 6
standard error, with p values referring to comparisons
between control (no oligomers) and individual treatment
groups.
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in the target vessel. This results in significant inhi-
bition of cell proliferation and the reduction in
medial damage that develops early in SVGs soon
after grafting. The antiproliferative effects of anti-
sense DNA are concentration and sequence depen-
dent. These findings provide the basis for further
studies of therapeutic potential of this approach to
prevent long-term failure of SVGs.
We are grateful to Tim Geiser, PhD, and Jerry Zon,
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